Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women (NCT07529249) | Clinical Trial Compass
Not Yet RecruitingPhase 1
Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women
France75 participantsStarted 2026-04
Plain-language summary
This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.
Who can participate
Age range45 Years – 70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant having signed an Informed Consent Form (ICF);
✓. Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;
✓. Participant with phototype II to IV according to the Fitzpatrick classification;
✓. Participant with dry skin measured on the cheeks (Tewameter, TEWL \>15g/m²/h (skin barrier integrity) on back of the cheekbone)
✓. Female Participant of non-childbearing potential, defined as a woman without uterus and/or both ovaries, surgically sterile (at least 6 months prior to Screening visit) or post-menopausal (at least one year post cessation of menses);
✓. Female Participant of childbearing potential who has been using a highly effective birth control method for at least 1 month prior to Screening visit and agreeing to continue adequate contraception during the entire study period;
✓. Participant agreeing not to apply any cosmetic product (e.g. care cream, lotion, body milk) or drug on the face (except usual cleansing products) within 24 hours before the study visits;
✓. Participant agreeing to not apply cosmetic, medical, or aesthetic treatments out of the study protocol on the face and legs during the whole study duration;
Exclusion criteria
✕. Participant with a BMI ≤17 or ≥30 kg/cm²;
✕. Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;
What they're measuring
1
Change in Facial Skin Barrier Integrity Measured by Tewameter After 3 Months of Supplementation
Timeframe: from baseline until the end of treatment at T3 months
Trial details
NCT IDNCT07529249
SponsorCentre de Pharmacologie Clinique Applique a la Dermatologie
✕. Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;
✕. Participant with an history of sleeve or bypass;
✕. Participant currently participating in another clinical study or being in an exclusion period of another clinical study;
✕. Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);
✕. Participant with a known allergy to beef-derived products;
✕. Participant who has used collagen supplements, vitamin C, or other skin related nutraceuticals within the last 3 months